Search Cancer Clinical Trials

Clinical Trials

Title	A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
Disease/Condition	Phase 1¸ Organ Dysfunction¸ and Other Experimental
Description	The primary purpose of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. The secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of ONO-7746 on CIT.
Eligibility Criteria	To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patient must be 18 Years and older * Subject must have experienced thrombocytopenia as evidenced by a platelet count less than 100 Gi/L in the preceding cycle immediately before study enrollment.
Principal Investigator	Sanjay Goel, MD
Phone	(718) 904-2488
Contact Email	sgoel@montefiore.org
Post Date	04/21/2011
Protocol Number	11-05-188/West
Status	Recruiting
Current Trial Type	Interventional